dilmapimod
Small moleculeexperimental
Clinical trial activity
10 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2005 (NCT00419809)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(F)ccc1-c1nc(NC(CO)CO)nc2c1ccc(=O)n2-c1c(F)cccc1F- Mol. weight
- 456.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2103838 ↗
Also known as
- dilmapimod
- dilmapimod
- dilmapimod
- dilmapimod
- gw681323
- gw681323
- sb681323
- sb-681323
- sb-681323
- sb-681323
- sb-681323
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00996840 | Phase 2 | Oct 1, 2009 | GlaxoSmithKline |
| NCT00564746 | Phase 1 | Sep 1, 2007 | GlaxoSmithKline |
| NCT00439881 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
| NCT00390845 | Phase 2 | Aug 1, 2006 | GlaxoSmithKline |
| NCT00291902 | Phase 2 | Mar 1, 2006 | GlaxoSmithKline |
| NCT00320450 | Phase 2 | Nov 1, 2005 | GlaxoSmithKline |
| NCT00144859 | Phase 2 | Jul 1, 2005 | GlaxoSmithKline |
| NCT00380133 | Phase 1 | Jun 1, 2005 | GlaxoSmithKline |
| NCT00134693 | Phase 2 | Jun 1, 2005 | GlaxoSmithKline |
| NCT00419809 | Phase 1 | May 1, 2005 | GlaxoSmithKline |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 10 | 10 | 2 | 2005 |
1 organizations
Page 1 / 1